Amicus Therapeutics Completes Merger with BioMarin, Becomes Wholly-Owned Subsidiary

summarizeSummary

Amicus Therapeutics, Inc. has completed its merger with BioMarin Pharmaceutical Inc.'s subsidiary, Lynx Merger Sub 1, Inc., resulting in Amicus becoming a wholly-owned subsidiary and terminating all public offerings.

check_boxKey Events

• Merger Completion Confirmed

  Amicus Therapeutics, Inc. has officially completed its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., making Amicus a wholly-owned subsidiary.

• Public Offerings Terminated

  All offerings and sales of securities under various S-3 Registration Statements have been terminated following the merger completion.

• Securities Deregistered

  Amicus is removing all registered but unsold securities from registration with the SEC, signifying the end of its public trading status.

auto_awesomeAnalysis

This filing confirms the definitive completion of the merger between Amicus Therapeutics and Lynx Merger Sub 1, Inc., a subsidiary of BioMarin Pharmaceutical Inc. This major corporate event transforms Amicus into a private entity, marking the end of its life as an independent publicly traded company. As a direct consequence, Amicus has initiated the deregistration of all previously registered but unsold securities. This follows the final French regulatory clearance announced on April 23, 2026, and finalizes the acquisition process. For existing shareholders, this event typically signifies the realization of the merger consideration.